15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $45M | -$3M | 85.0% | -6.3% | -11.4% | -3.7% | $5M | — | $11M |
| 2024 | $38M | -$6M | 82.6% | -17.0% | -28.4% | -8.6% | -$678647 | — | $18M |
| 2023 | $40M | -$6M | 84.7% | -24.2% | -21.2% | -7.7% | $6M | — | $18M |
| 2022 | $42M | -$6M | 78.3% | -13.6% | -15.4% | -6.0% | $8M | — | $20M |
| 2021 | $35M | -$4M | 74.9% | -21.9% | -8.2% | -4.2% | $6M | — | $27M |
| 2020 | $36M | -$3M | 75.9% | -17.8% | -7.1% | -3.5% | $5M | — | $25M |
| 2019 | $32M | -$4M | 77.1% | -28.7% | -6.9% | -3.4% | $3M | — | $28M |
| 2018 | $29M | -$7M | 79.1% | -38.8% | -12.5% | -6.2% | $3M | — | $28M |
| 2017 | $26M | -$8M | 78.8% | -34.8% | -12.4% | -8.6% | -$833674 | — | $45M |
| 2016 | $32M | -$944683 | 81.7% | -4.4% | -1.3% | -1.0% | $438606 | — | $35M |
| 2015 | — | $731351 | — | — | 1.0% | 0.8% | $6M | — | $38M |
| 2014 | — | $2M | — | — | 3.0% | 2.5% | $7M | — | $40M |
| 2013 | — | -$2M | — | — | -2.6% | -2.4% | $648714 | — | $41M |
| 2012 | — | $6M | — | — | 6.8% | 5.9% | $7M | — | $54M |
| 2011 | — | $6M | — | — | 6.8% | 5.9% | $8M | — | $71M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $9M | -$4M | 0.0% | -35.9% | -24.5% | -6.8% | — | — | $4M |
| Mar '26 | $9M | -$3M | 78.8% | -34.3% | -15.2% | -4.6% | $387025 | — | $11M |
| Dec '25 | $14M | -$1M | 83.6% | -10.0% | -5.7% | -1.8% | $3025 | — | $11M |
| Sep '25 | $8M | -$2M | 88.1% | -23.7% | -7.4% | -2.9% | $163392 | — | $15M |
| Jun '25 | $11M | -$740740 | 81.4% | -28.8% | -2.6% | -1.1% | $817315 | — | $16M |
| Mar '25 | $12M | $1M | 87.8% | 11.0% | 4.4% | 1.8% | $4M | — | $15M |
| Dec '24 | $10M | -$2M | 81.1% | -17.7% | -8.3% | -2.5% | $2M | — | $18M |
| Sep '24 | $9M | -$2M | 85.4% | -18.6% | -6.2% | -2.0% | $460124 | — | $17M |
| Jun '24 | $10M | -$1M | 82.6% | -10.4% | -4.1% | -1.4% | -$862838 | — | $17M |
| Mar '24 | $8M | -$2M | 81.5% | -22.0% | -7.1% | -2.4% | -$2M | — | $19M |
| Dec '23 | $9M | -$6M | 83.6% | -66.1% | -21.3% | -7.7% | $991448 | — | $18M |
| Sep '23 | $10M | -$1M | 82.5% | -18.5% | -2.9% | -1.2% | $1M | — | $19M |
| Jun '23 | $11M | $872200 | 86.0% | 0.2% | 2.3% | 1.0% | $5M | — | $18M |
| Mar '23 | $9M | $192184 | 86.4% | -16.6% | 0.5% | 0.2% | -$2M | — | $16M |
| Dec '22 | $9M | -$2M | 71.0% | -25.0% | -6.7% | -2.6% | $4M | — | $20M |
| Sep '22 | $11M | -$408639 | 80.5% | -2.5% | -1.1% | -0.5% | $3M | — | $20M |
| Jun '22 | $10M | -$1M | 80.3% | -17.9% | -3.4% | -1.4% | $2M | — | $18M |
| Mar '22 | $11M | -$1M | 80.2% | -11.6% | -3.4% | -1.4% | -$177484 | — | $17M |
| Dec '21 | $7M | -$4M | 54.9% | -59.0% | -9.0% | -4.6% | $2M | — | $27M |
| Sep '21 | $8M | -$1M | 83.5% | -19.4% | -2.3% | -1.2% | -$161961 | — | $26M |
How the market has priced CPIX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, CUMBERLAND PHARMACEUTICALS INC's revenue has grown 4.4% per year. These are computed facts, not advice.
As of FY2025, CUMBERLAND PHARMACEUTICALS INC reported — of total debt against $11M of cash; operating income covered interest expense -5.6×.
In FY2025, gross margin was 85.0%, operating margin -6.3%, and net margin -6.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.